When.com Web Search

  1. Ad

    related to: roche drug

Search results

  1. Results From The WOW.Com Content Network
  2. Roche - Wikipedia

    en.wikipedia.org/wiki/Roche

    Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002. Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead ...

  3. Roche shares jump on obesity drug results from early ... - AOL

    www.aol.com/news/roche-shares-gain-obesity-drug...

    (Reuters) -Roche shares gained as much as 4.7% on Thursday after an early-stage trial showed that a newly-acquired obesity drug candidate led to significant weight loss, a key step in Swiss ...

  4. US FDA approves Roche's drug for a chronic blood disorder ...

    www.aol.com/news/us-fda-approves-roches-drug...

    The U.S. Food and Drug Administration on Thursday approved Roche's drug for a chronic blood disorder, the Swiss drugmaker said. The drug crovalimab, branded as PiaSky, is a monthly under-the-skin ...

  5. Roche's Antiviral Drug Reduces Transmission Of Influenza ...

    www.aol.com/roches-antiviral-drug-reduces...

    On Thursday, Roche Holdings AG (OTC:RHHBY) released positive topline results of the phase 3 CENTERSTONE study of Xofluza (baloxavir marboxil), an antiviral that showed a reduction in the ...

  6. Roche joins race for obesity drugs with $2.7 billion ... - AOL

    www.aol.com/news/roche-enters-obesity-drug...

    Roche agreed to take over obesity drug developer Carmot Therapeutics for $2.7 billion, joining a list global contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk ...

  7. Roche To Ride Booming Obesity Treatment Market With Newly ...

    www.aol.com/roche-ride-booming-obesity-treatment...

    Thursday, Genentech, a unit of Roche Holdings AG (OTC:RHHBY), released results from the Phase 1b trial of CT-388, a dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and ...

  8. Venetoclax - Wikipedia

    en.wikipedia.org/wiki/Venetoclax

    It is marketed by both Abbvie and Genentech USA, which is a member of the Roche Group. [14] AbbVie and Genentech are both commercializing the drug within the United States, but only AbbVie has rights to do so outside of the U.S. [20] According to Reuters 2016 Drugs to Watch, the 2020 forecast sales for venetoclax are US$1.48 billion.

  9. Roche Fast-Tracks Obesity Drug Development, Eyes Over $3B ...

    www.aol.com/finance/roche-fast-tracks-obesity...

    In line with its broader strategy, Roche plans to cut drug development costs by 20% and reduce the time it takes for drugs to move from discovery to the end of Phase 3 trials by 40%, aiming to ...